milliplex map rat kidney toxicity magnetic bead panel 2 Search Results


milliplex® map human kidney toxicity panel 2  (Merck KGaA)
90
Merck KGaA milliplex® map human kidney toxicity panel 2
Milliplex® Map Human Kidney Toxicity Panel 2, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/milliplex+map+rat+kidney+toxicity+magnetic+bead+panel+2/3+plex+human+kidney+injury+magnetic+bead+panel+4/pmc03231866-78-0-15
Average 90 stars, based on 1 article reviews
milliplex® map human kidney toxicity panel 2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aution max ax-4280  (ARKRAY Inc)
90
ARKRAY Inc aution max ax-4280
Aution Max Ax 4280, supplied by ARKRAY Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/milliplex+map+rat+kidney+toxicity+magnetic+bead+panel+2/reflectance+colorimetry+arkray+ax4280/pmc05363415-197-0-6
Average 90 stars, based on 1 article reviews
aution max ax-4280 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
discovery® kidney injury panel 2  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC discovery® kidney injury panel 2
Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary <t>biomarkers</t> are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted
Discovery® Kidney Injury Panel 2, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/milliplex+map+rat+kidney+toxicity+magnetic+bead+panel+2/kidney+injury+panel+1+assay/pmc03231866-593-9-24
Average 90 stars, based on 1 article reviews
discovery® kidney injury panel 2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
discovery® kidney injury panel 1  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC discovery® kidney injury panel 1
Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary <t>biomarkers</t> are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted
Discovery® Kidney Injury Panel 1, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/milliplex+map+rat+kidney+toxicity+magnetic+bead+panel+2/kidney+injury+panel+1++rat++assay+kit/pmc03231866-485-9-198
Average 90 stars, based on 1 article reviews
discovery® kidney injury panel 1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
milliplex ® map custom human 2-plex magnetic bead panel  (Merck KGaA)
90
Merck KGaA milliplex ® map custom human 2-plex magnetic bead panel
Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary <t>biomarkers</t> are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted
Milliplex ® Map Custom Human 2 Plex Magnetic Bead Panel, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/milliplex+map+rat+kidney+toxicity+magnetic+bead+panel+2/milliplex+map+human+cytokine+chemokine+panel/pmc08495315-180-65-77
Average 90 stars, based on 1 article reviews
milliplex ® map custom human 2-plex magnetic bead panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
magpix device  (Merck KGaA)
90
Merck KGaA magpix device
Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary <t>biomarkers</t> are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted
Magpix Device, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/milliplex+map+rat+kidney+toxicity+magnetic+bead+panel+2/magpix+device/pmc08495315-180-22-24
Average 90 stars, based on 1 article reviews
magpix device - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary biomarkers are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary biomarkers are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery®

Techniques:

Shown is an integrated approach for the inclusion of novel Omics data in the toxicological routine safety assessment and the identification and implementation of novel biomarkers into the standard battery or else for the submission to the FDA/EMA qualification process. Figure adapted by (45)

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Shown is an integrated approach for the inclusion of novel Omics data in the toxicological routine safety assessment and the identification and implementation of novel biomarkers into the standard battery or else for the submission to the FDA/EMA qualification process. Figure adapted by (45)

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery®

Techniques: Battery

Shown are several urinary biomarkers with their predictive area within the nephron. These biomarkers include qualified as well as exploratory once

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Shown are several urinary biomarkers with their predictive area within the nephron. These biomarkers include qualified as well as exploratory once

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery®

Techniques:

Overview of the Accepted Biomarkers for the Detection of Nephrotoxicity Including their Physiological Function, the Area of Toxicity Prediction, as well as Preclinical and Clinical Data Available

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Overview of the Accepted Biomarkers for the Detection of Nephrotoxicity Including their Physiological Function, the Area of Toxicity Prediction, as well as Preclinical and Clinical Data Available

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery®

Techniques: Marker, Filtration, Expressing, Clinical Proteomics, Membrane

The Current Status of the Originally Qualified Seven Urinary Protein Biomarkers and There Voluntary Usability in Clinical Trials Recommended by the ICH-Regulated Agencies

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: The Current Status of the Originally Qualified Seven Urinary Protein Biomarkers and There Voluntary Usability in Clinical Trials Recommended by the ICH-Regulated Agencies

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF WidescreenTM Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery®

Techniques: Clinical Proteomics, Biomarker Discovery

Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary biomarkers are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Only substantial loss of renal biomass leads to a lack of renal functionality. Traditional clinical–chemical parameters like serum creatinine or BUN only detected this decrease in kidney function. The novel urinary biomarkers are accepted to detect renal damage earlier because not the function but the damage of tissue was predicted

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery® Mesoscale Discovery® Mesoscale Discovery® (MSD) provides an alternative multiplexing technology platform, able to detect novel protein biomarkers.

Techniques:

Shown is an integrated approach for the inclusion of novel Omics data in the toxicological routine safety assessment and the identification and implementation of novel biomarkers into the standard battery or else for the submission to the FDA/EMA qualification process. Figure adapted by (45)

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Shown is an integrated approach for the inclusion of novel Omics data in the toxicological routine safety assessment and the identification and implementation of novel biomarkers into the standard battery or else for the submission to the FDA/EMA qualification process. Figure adapted by (45)

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery® Mesoscale Discovery® Mesoscale Discovery® (MSD) provides an alternative multiplexing technology platform, able to detect novel protein biomarkers.

Techniques:

Shown are several urinary biomarkers with their predictive area within the nephron. These biomarkers include qualified as well as exploratory once

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Shown are several urinary biomarkers with their predictive area within the nephron. These biomarkers include qualified as well as exploratory once

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery® Mesoscale Discovery® Mesoscale Discovery® (MSD) provides an alternative multiplexing technology platform, able to detect novel protein biomarkers.

Techniques:

Overview of the Accepted Biomarkers for the Detection of Nephrotoxicity Including their Physiological Function, the Area of Toxicity Prediction, as well as Preclinical and Clinical Data Available

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: Overview of the Accepted Biomarkers for the Detection of Nephrotoxicity Including their Physiological Function, the Area of Toxicity Prediction, as well as Preclinical and Clinical Data Available

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery® Mesoscale Discovery® Mesoscale Discovery® (MSD) provides an alternative multiplexing technology platform, able to detect novel protein biomarkers.

Techniques: Marker, Filtration, Expressing

The Current Status of the Originally Qualified Seven Urinary Protein Biomarkers and There Voluntary Usability in Clinical Trials Recommended by the ICH-Regulated Agencies

Journal: The AAPS Journal

Article Title: Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity--An Overview for Applied Toxicology

doi: 10.1208/s12248-011-9301-x

Figure Lengend Snippet: The Current Status of the Originally Qualified Seven Urinary Protein Biomarkers and There Voluntary Usability in Clinical Trials Recommended by the ICH-Regulated Agencies

Article Snippet: An overview of kits available for the detection of protein biomarkers for the detection of renal damage based on the Luminex® xMAP® and the MesoScale Discovery® platform is shown in Table . table ft1 table-wrap mode="anchored" t5 Table IV caption a7 Assay name Species Matrix Analytes Provider/company Luminex® xMAP® Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) α-GST Merck-Millipore formerly Merck-Chemicals Timp-1 Kim-1 β-2-Microglobulin VEGF Widescreen™ Rat Kidney Toxicity Panel 1 Rat Urine (serum) Calbindin Merck-Millipore formerly Merck-Chemicals Clusterin NGAL Cystatin C Osteopontin Rat Kidney MAP v. 1.0 Rat Urine (serum) β-2-Microglobulin Rules-based Medicine Calbindin Clusterin Cystatin-C EGF α-GST m-GST Kim-1 NGAL Osteopontin Timp-1 VEGF-A MILLIPLEX® MAP Human Kidney Toxicity Panel 1 Human Serum KIM-1 Merck-Millipore formerly Millipore Osteopontin Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 2 Human Serum β-2-Microglobulin Merck-Millipore formerly Millipore Clusterin Cystatin C MILLIPLEX® MAP Human Kidney Toxicity Panel 3 Human Urine KIM-1 Merck-Millipore formerly Millipore Renin TFF-3 MILLIPLEX® MAP Human Kidney Toxicity Panel 4 Human Urine Albumin Merck-Millipore Formerly Millipore β-2-Microglobulin Clusterin Cystein C Osteopontin Human Kidney MAP v. 1.0 Human Urine (serum) α-2-Microglobulin Rules-based medicine β-2-Microglobulin Calbindin Clusterin CTGF Creatinine Cystatin-C α-GST Kim-1 Microalbumin NGAL Osteopontin Uromodulin Timp-1 TFF-3 VEGF-A OPG MesoScale Discovery® Kidney Injury Panel 1 Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin Kidney Injury Panel 2 a Rat Urine Albumin MesoScale discovery Kim-1 NGAL Osteopontin α-GST Clusterin Argutus AKI Test® Rat Urine α-GST MesoScale Discovery/Argutus Medical Ltd. GSTYb1 RPA-1 Open in a separate window a Commercialization of the Kidney Injury Panel 2 is planned for end of 2011 Summary of Commercial Available Multiplex Assays Based on the Luminex® xMAP® Technology and the MULTI-Array® Technology from MesoScale Discovery® Mesoscale Discovery® Mesoscale Discovery® (MSD) provides an alternative multiplexing technology platform, able to detect novel protein biomarkers.

Techniques: Biomarker Assay